載入中
NASDAQHealthcareMedical - Pharmaceuticals
最新資料
US$79.78
+US$1.03 · +1.31%
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
前收盤價
US$79.78
+US$1.03 · +1.31%
盤中時間採用ET。市場資料可能有所延遲。
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
日內區間
目前US$79.78
52週區間
目前US$79.78
盤中時間採用ET。市場資料可能有所延遲。
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
日內區間
目前US$79.78
52週區間
目前US$79.78
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6.78億 USD | 4.23億 USD | 2.7億 USD | 2.2億 USD | 3854.4萬 USD |
| 銷貨成本 | 3.07億 USD | 6091萬 USD | 5652.4萬 USD | 2289.5萬 USD | 910萬 USD |
| 毛利 | 3.7億 USD | 3.62億 USD | 2.14億 USD | 1.97億 USD | 2944.4萬 USD |
| 研究與開發 | 9685.3萬 USD | 1.12億 USD | 7609.7萬 USD | 6549萬 USD | 9929.7萬 USD |
| 銷售、一般及管理費用 | 1.96億 USD | 1.68億 USD | 1.29億 USD | 9795.1萬 USD | 8594.8萬 USD |
| 營業費用 | 2.93億 USD | 4.08億 USD | 2.39億 USD | 1.88億 USD | 1.86億 USD |
| 利息收入 | 1164.7萬 USD | 946.4萬 USD | 854.4萬 USD | 125.3萬 USD | 9.7萬 USD |
| 折舊和攤銷 | 155.4萬 USD | 169.5萬 USD | 234.1萬 USD | 240.2萬 USD | 235.5萬 USD |
| 營業利益 | 7722.1萬 USD | −4561.6萬 USD | −2519.6萬 USD | 977.3萬 USD | −1.57億 USD |
| 淨利 | 5900.5萬 USD | −4319.3萬 USD | 1408.4萬 USD | 1.83億 USD | −1.58億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.04億0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM9452.17萬0.12%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB7534.7萬0.04%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK4338.65萬0.09%447億 USD0.05%US$344.74+1.22%
iShares Russell 2000 Growth ETFIWO3323.04萬0.24%139.17億 USD0.24%US$356.78+0.94%
Dimensional - US Small Cap ETFDFAS2522.03萬0.07%338.69億 USD0.31%US$78.35+0.32%
Vanguard Russell 2000 ETFVTWO1915.77萬0.10%180億 USD0.06%US$112.66+0.50%
Dimensional - US Core Equity 2 ETFDFAC1232.11萬0.01%885.96億 USD0.21%US$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWODimensional - US Core Equity 2 ETFDFACAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
